FAQ: GeoVax Participation in ROTH Healthcare Opportunities Conference 2025

What is the main purpose of GeoVax’s participation in this conference?

GeoVax’s Chairman and CEO David Dodd will participate to meet with institutional investors and discuss the company’s pipeline progress, including their Mpox/smallpox vaccine, COVID-19 vaccine, and cancer therapy programs.

When and where is the ROTH Healthcare Opportunities Conference taking place?

The conference is scheduled for Thursday, October 9, 2025, at the Yale Club in New York City.

What specific GeoVax programs will be discussed at the conference?

Mr. Dodd will discuss GEO-MVA (Mpox/smallpox vaccine), GEO-CM04S1 (multi-antigen COVID-19 vaccine in three Phase 2 trials), and Gedeptin® (gene-directed enzyme prodrug therapy for solid tumors with a planned Phase 2 trial in head and neck cancer).

What is unique about the GEO-MVA vaccine program?

GEO-MVA is an MVA-based Mpox/smallpox vaccine positioned for global preparedness and stockpile strategies, and it recently received favorable Scientific Advice from the European Medicines Agency (EMA).

How is GeoVax’s COVID-19 vaccine different from current options?

GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients, a booster for CLL patients, and a more robust, durable booster for healthy patients who previously received mRNA vaccines.

What type of event is the ROTH Healthcare Opportunities Conference?

It’s an invite-only event designed to connect innovative healthcare companies with institutional investors through 1-on-1 meetings, small group meetings, and themed panel discussions.

How can investors schedule meetings with GeoVax leadership?

Investors seeking to schedule meetings should contact their ROTH representative.

What is the significance of the EMA’s Scientific Advice for GEO-MVA?

Based on the favorable EMA regulatory guidance, GeoVax anticipates progressing directly to a Phase 3 clinical evaluation for GEO-MVA, omitting Phase 1 and Phase 2 trials.

What patient populations are being studied in GeoVax’s COVID-19 vaccine trials?

The COVID-19 vaccine is being evaluated in immunocompromised individuals, patients with chronic lymphocytic leukemia (CLL), and healthy adults who previously received mRNA vaccines.